pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

846 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT786Endpoints593BioPharma Dive228onclive165BioSpace63Fierce Biotech63raps25
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • Incyte CEO sees $2B Vega deal aiding a post-Jakafi future
    Bill Meury has been in or led the C-suite of several biopharma companies that have constructed multibillion-dollar exits over the past decade: Allergan, Karuna and Anthos. Now, he’s the one buyin…
    Endpoints · 1mo ago↗ source
  • City Therapeutics gets $99M to gather data on three RNAi medicines
    City Therapeutics, the next-gen RNAi startup founded and led by former Alnylam executives, has collected $99.5 million to fund the clinical development of its first three candidates and expand into…
    Endpoints · 1mo ago↗ source
  • Roche stakes $700M on Nurix’s protein-degrading drug
    <p>Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.</p>
← prev
page 18 of 34
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
BioPharma Dive · 1mo ago
↗ source
  • GoHealth files for bankruptcy, as Medicare Advantage insurers pull back
    The volatile Medicare Advantage market can now count GoHealth as a casualty. GoHealth, a health insurance marketplace focused on seniors, on Sunday voluntarily filed for Chapter 11 bankruptcy in…
    Endpoints · 1mo ago↗ source
  • Tango data add to growing momentum for pancreatic cancer drugs
    <figure><div><img src="https://imgproxy.divecdn.com/WEayUdfuHXoOw2FpmsOFLF4yn7KYNOFOwzm5w7xXaT4/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMzE4Mjc5OTExLmpwZ…
    BioPharma Dive · 1mo ago↗ source
  • Incyte to buy blood disorder drug in possibly $2B deal
    <figure><div><img src="https://imgproxy.divecdn.com/2QfDLQx7Ry-HALZnt9wJeCfUZIiqFEeEOc-a7yHR_O8/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMzY2OTU4MDU4LmpwZ…
    BioPharma Dive · 1mo ago↗ source
  • J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B
    <figure><div><img src="https://imgproxy.divecdn.com/8ktp2N_0bECPaVaqEXe_a9D0QIm8s6Dv94O0ycnj0SA/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9KSl9Mb2JieTAxX0hpZ2hSZXNfQzlXdTlwT…
    BioPharma Dive · 1mo ago↗ source
  • Treeline to go public via reverse merger with Standard BioTools
    Treeline Biosciences has shared plans to debut on public markets through a reverse merger with Standard BioTools in a move that should give the company a cash runway through 2029. The
    Endpoints · 1mo ago↗ source
  • ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
    <figure><div><img src="https://imgproxy.divecdn.com/s1OP69WlFaq8Ze7MFeyEVPnIDEywrEml5dBx5ZtKpus/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNjY1Nzc4NTU4XzEua…
    BioPharma Dive · 1mo ago↗ source
  • J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS field
    Johnson & Johnson is making another early-stage oncology deal, dishing out $1 billion in cash to acquire Firefly Bio, a preclinical startup working on degrader antibody conjugates. J&J no…
    Endpoints · 1mo ago↗ source
  • GSK inks multi-target pact with Engitix; Sangamo considers strategic options
    Plus news about Pfizer's latest label expansion. 🤝 GSK inks multi-target liver pact with Engitix: London-based Engitix will use disease models based on its extracellular matrix technology to ide…
    Endpoints · 1mo ago↗ source
  • Tango plans Phase 3 pancreatic cancer study after combo success
    Will 2026 be remembered as the year when pancreatic cancer finally became treatable? Following Revolution Medicines’ smashing success at the annual American Society of Clinical Oncology meeting l…
    Endpoints · 1mo ago↗ source
  • Coming Soon
    Next installments of the biopharma pay series coming soon
    Endpoints · 1mo ago↗ source
  • Biopharma's top-paid CEOs of 2025: 25 making $25M+
    For the first time in four years, Endpoints News is raising the bar for what it means to be a top-paid CEO. The previous floor of $20 million is no longer rich enough. The biopharma ...
    Endpoints · 1mo ago↗ source
  • Cavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugs
    Cavalry Biosciences, the first biotech out of incubator and investor Jupiter Bioventures, is working on a $75 million Series B to bring its first two drug candidates into clinical testing, CEO Pres…
    Endpoints · 1mo ago↗ source
  • #ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shot
    The molecules known as triple-Gs — agonists of GLP-1, GIP and glucagon — are drawing attention as data build suggesting they could be the most effective class of obesity drugs. Eli Lilly is leading…
    Endpoints · 1mo ago↗ source
  • Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront deal
    Incyte plans to spend $1.25 billion upfront to buy Star Therapeutics' subsidiary Vega Therapeutics and its Phase 3 bleeding disorder candidate, the companies said Monday. The deal package also incl…
    Endpoints · 1mo ago↗ source
  • Takeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appeal
    Takeda has updated its financial results to reflect costs it could incur after losing an antitrust lawsuit concerning its laxative drug Amitiza. In May, the US District Court in Massachusetts rul…
    Endpoints · 1mo ago↗ source
  • Nurix to work with Roche on BTK degrader in pact worth up to $2.3B
    Roche is set to pay Nurix Therapeutics $700 million upfront to collaborate on a BTK degrader for B cell malignancies, with broader plans in immunology and neurology. The deal could be ...
    Endpoints · 1mo ago↗ source
  • Innovation alone is no longer enough in biopharma
    <p>In biopharma, the next edge may come from the systems that turn discovery into scale.</p>
    BioPharma Dive · 1mo ago↗ source
  • Precision under pressure: Logistic solutions for nuclear medicine scalability
    <p>Racing the clock: How precision logistics deliver life-saving nuclear medicine.</p>
    BioPharma Dive · 1mo ago↗ source
  • #ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effects
    Boehringer Ingelheim’s obesity asset survodutide, which it licensed from Zealand Pharma, has shown high rates of discontinuations in its Phase 3 obesity study. In April, data from the SYNCHRONIZE…
    Endpoints · 1mo ago↗ source
  • #ADA26: Pfizer's monthly shot shows effect on obesity, diabetes
    The long-acting GLP-1 shot that was the centerpiece of Pfizer’s acquisition of Metsera last year looks effective in patients with both obesity and diabetes, according to data presented Saturday.…
    Endpoints · 1mo ago↗ source
  • #ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this year
    Roche says it has one obesity drug with a potential best-in-class safety profile, and another with a similar shot at leading in efficacy. Combining them could produce a highly successful product if…
    Endpoints · 1mo ago↗ source
  • Lawmakers propose China restrictions; #ASCO26 recap; and more
    Welcome back to Endpoints Weekly! We had a small team in Chicago last weekend at this year’s ASCO conference. You’ll find a recap of their coverage below, including more details on Revolution Medic…
    Endpoints · 1mo ago↗ source